A Phase 3 interventional study of PhXA41 and timolol in Glaucoma, Open Angle Glaucoma and Ocular Hypertension, sponsored by Pfizer. Completed at 17 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-03-25.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
PhXA41 is not inferior to timolol
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 268 is above the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients currently not treated or on single-drug treatment for the elevated IOP are eligible after a medication free period (wash-out) of:
Exclusion Criteria:
Drug: timolol
Drug: PhXA41
One drop in the affected eye once daily for six months.
One drop in the affected eye twice daily for six months.
to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
Time frame: 6 mos
to describe the IOP development throughout the study period and to follow the safety variables in the two treatment groups.
Time frame: 6 mos
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer